Cover Image
市場調查報告書

Celgene Corporation:產品平台分析

Celgene Corporation - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251651
出版日期 內容資訊 英文 173 Pages
訂單完成後即時交付
價格
Back to Top
Celgene Corporation:產品平台分析 Celgene Corporation - Product Pipeline Review - 2016
出版日期: 2016年03月30日 內容資訊: 英文 173 Pages
簡介

Celgene Corporation,研究、開發、製造癌症及免疫疾病·發炎性疾病相關治療藥的生物醫藥品企業。

本報告提供Celgene Corporation的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Celgene Corporation的基本資料

Celgene Corporation概要

  • 主要資訊
  • 企業資料

Celgene Corporation:R&D概要

  • 主要的治療範圍

Celgene Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Celgene Corporation:開發中產品概況

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 申請未受理/被撤消產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Celgene Corporation:藥物簡介

  • apremilast
  • lenalidomide
  • romidepsin
  • amrubicin hydrochloride
  • azacitidine
  • paclitaxel
  • pomalidomide
  • CC-223
  • CC-11050
  • CC-292
  • cenplacel-L
  • GED-0301
  • CC-115
  • ARRY-382
  • CC-122
  • CC-220
  • CC-90001
  • EPZ-5676
  • GI-6301
  • PDA-002
  • UCB + HPDSC
  • ABI-013
  • AVL-181
  • AVL-192
  • CC-0730671
  • CC-2142
  • CC-509
  • CC-539
  • CC-90002
  • CC-90003
  • CNX-1351
  • CTP-730
  • IMiDxl
  • 癌症及發炎性疾病的小分子
  • CC-0739623
  • CC-2141
  • CSC-1
  • 發炎性疾病的激酶抑制劑
  • 血液疾病及癌症的醫藥品
  • EPIpros-1
  • EPIpros-2等

Celgene Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Celgene Corporation:最近的開發平台趨勢

Celgene Corporation:暫停中的計劃

Celgene Corporation:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • CC-1088
    • satraplatin

Celgene Corporation:企業發表

Celgene Corporation:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08004CDB

Summary

Global Markets Direct's, 'Celgene Corporation - Product Pipeline Review - 2016', provides an overview of the Celgene Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Celgene Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Celgene Corporation
  • The report provides overview of Celgene Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Celgene Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Celgene Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Celgene Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Celgene Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Celgene Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Celgene Corporation Snapshot
    • Celgene Corporation Overview
    • Key Information
    • Key Facts
  • Celgene Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Celgene Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Celgene Corporation - Pipeline Products Glance
  • Celgene Corporation - Late Stage Pipeline Products
  • Celgene Corporation - Clinical Stage Pipeline Products
  • Celgene Corporation - Early Stage Pipeline Products
  • Celgene Corporation - Drug Profiles
    • apremilast
    • lenalidomide
    • azacitidine
    • CC-90007
    • mongersen
    • paclitaxel albumin bound
    • pomalidomide
    • romidepsin
    • amrubicin hydrochloride
    • CC-11050
    • CC-220
    • GI-6207
    • GI-6301
    • PDA-002
    • spebrutinib besylate
    • Stem Cell Therapy for Hematological Malignancies, Non-Malignant Disorders and Hypoxic-ischemic Encephalopathy
    • CC-122
    • CC-223
    • PNK-007
    • CC-115
    • CC-90001
    • CC-90002
    • CC-90003
    • CC-90005
    • Cellular Immunotherapy to Target GD2 for Neuroblastoma
    • CTP-730
    • pinometostat
    • AVL-181
    • AVL-192
    • CC-0730671
    • CC-2142
    • CC-509
    • CC-539
    • Monoclonal Antibody 1 for Inflammation
    • Monoclonal Antibody 2 for Inflammation
    • Small Molecules for Undisclosed Indication
    • Small Molecules to Agonize ROR gamma for Breast Cancer
    • Antibody for Oncology
    • Antibody for Undisclosed Indication
    • CC-0739623
    • CC-2141
    • CC-90006
    • CC-90008
    • CC-90009
    • CC-90010
    • CC-90011
    • CSC-1
    • Drug for Hematological Disorders and Oncology
    • Drug to Inhibit Kinase for Inflammation
    • Drugs for Hematology and Oncology
    • Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS
    • Small Molecule to Inhibit Brutons Tyrosine Kinase for Inflammation
    • Small Molecules for Inflammation
    • Small Molecules for Inflammation and Cancer
    • Small Molecules for Malaria
  • Celgene Corporation - Pipeline Analysis
    • Celgene Corporation - Pipeline Products by Target
    • Celgene Corporation - Pipeline Products by Route of Administration
    • Celgene Corporation - Pipeline Products by Molecule Type
    • Celgene Corporation - Pipeline Products by Mechanism of Action
  • Celgene Corporation - Recent Pipeline Updates
  • Celgene Corporation - Dormant Projects
  • Celgene Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Celgene Corporation - Company Statement
  • Celgene Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Celgene Corporation, Key Information
  • Celgene Corporation, Key Facts
  • Celgene Corporation - Pipeline by Indication, 2016
  • Celgene Corporation - Pipeline by Stage of Development, 2016
  • Celgene Corporation - Monotherapy Products in Pipeline, 2016
  • Celgene Corporation - Partnered Products in Pipeline, 2016
  • Celgene Corporation - Partnered Products/ Combination Treatment Modalities, 2016
  • Celgene Corporation - Out-Licensed Products in Pipeline, 2016
  • Celgene Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Celgene Corporation - Pre-Registration, 2016
  • Celgene Corporation - Phase III, 2016
  • Celgene Corporation - Phase II, 2016
  • Celgene Corporation - Phase I, 2016
  • Celgene Corporation - Preclinical, 2016
  • Celgene Corporation - Discovery, 2016
  • Celgene Corporation - Pipeline by Target, 2016
  • Celgene Corporation - Pipeline by Route of Administration, 2016
  • Celgene Corporation - Pipeline by Molecule Type, 2016
  • Celgene Corporation - Pipeline Products by Mechanism of Action, 2016
  • Celgene Corporation - Recent Pipeline Updates, 2016
  • Celgene Corporation - Dormant Developmental Projects,2016
  • Celgene Corporation - Discontinued Pipeline Products, 2016
  • Celgene Corporation, Other Locations
  • Celgene Corporation, Subsidiaries

List of Figures

  • Celgene Corporation - Pipeline by Top 10 Indication, 2016
  • Celgene Corporation - Pipeline by Stage of Development, 2016
  • Celgene Corporation - Monotherapy Products in Pipeline, 2016
  • Celgene Corporation - Partnered Products in Pipeline, 2016
  • Celgene Corporation - Out-Licensed Products in Pipeline, 2016
  • Celgene Corporation - Pipeline by Top 10 Target, 2016
  • Celgene Corporation - Pipeline by Route of Administration, 2016
  • Celgene Corporation - Pipeline by Molecule Type, 2016
  • Celgene Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top